



Research and Development on Therapeutic Agents and Vaccines for COVID-19

Guest Editors:

Dr. Ahmed Kamal

Birla Institute of Technology & Science, Pilani Hyderabad Campus, Dist.- Medchal, Telangana 500 078, India

Dr. Swapna Ponnampalli

CVR College of Engineering, Mangalpalle, Hyderabad, India

Deadline for manuscript submissions:

closed (30 November 2023)

Message from the Guest Editors

The impact of the COVID-19 pandemic on humankind is persistent, despite the availability of a number of vaccines and some approved therapeutic agents. The continuous evolution of SARS-CoV-2 demands a broadly neutralizing therapy against current and emergent variants that may be helpful for both prevention and treatment. SARS-CoV-2 may not be the last human coronavirus to emerge from animals. To understand the virus replication and mutation mechanism, close monitoring of their populations in the early stages and the investigation of new druggable targets are promising strategies.

We invite contributions from the international community of researchers for this Special Issue on the ongoing progress in COVID-19 research. The goal of this Special Issue is to communicate the recent advances in the domain to the scientific community which may help to focus on the new strategies for containing the COVID-19 virus. Research areas may include (but are not limited to) the discovery of vaccines or drugs/drug targets and the ongoing research and development of vaccines and therapeutic strategies to fight against SARS-CoV-2.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)